4.4 Review

Jackhammer Esophagus Current Concepts and Dilemmas

期刊

JOURNAL OF CLINICAL GASTROENTEROLOGY
卷 55, 期 5, 页码 369-379

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCG.0000000000001472

关键词

chest pain; dysphagia; esophageal motility disorders; gastroesophageal reflux; high-resolution esophageal manometry

向作者/读者索取更多资源

Jackhammer esophagus (JE) is a newly recognized esophageal motility disorder characterized by hypercontractile peristalsis. It predominantly affects women with an average age of 65.2 years, presenting with dysphagia, reflux, and chest pain. The cause and pathogenesis remain unclear, with a variety of associated conditions, and treatment efficacy is largely anecdotal with insufficient study.
Jackhammer esophagus (JE) is a recently recognized esophageal motility disorder that is characterized by hypercontractile peristalsis. More than 500 cases have been reported in the literature. Among patients referred for esophageal motility disorders, the prevalence of JE ranges from 0.42% to 9%, with most series describing a prevalence of 2% to 4%. Most cases are women (60.5%). The mean reported age of patients with JE is 65.2 years, and patients commonly have dysphagia (62.8%). Reflux symptoms occur in similar to 40% of patients, and chest pain affects more than one-third of patients (36.4%). JE is a heterogenous disorder that is associated with several conditions, including obesity, opioid use, lung transplantation, eosinophilic infiltration of the esophagus, neoplasia, and systemic diseases. The cause and pathogenesis remain unknown, but several observations suggest that it is the result of multiple conditions that likely precipitate increased excitation and abnormal inhibition of neuromuscular function. The natural course of JE also is unknown, but progression to achalasia has been observed in a few patients. Treatment is challenging, in part because of the insufficient understanding of the disorder's underlying mechanisms. Various therapeutic modalities have been used, ranging from observation only to pharmacologic and endoscopic interventions (eg, botulinum toxin injection) to peroral endoscopic myotomy. Treatment efficacy remains largely anecdotal and insufficiently studied.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据